Last reviewed · How we verify
MOR106 single ascending doses, intravenous
MOR106 single ascending doses, intravenous is a Small molecule drug developed by Galapagos NV. It is currently in Phase 1 development.
At a glance
| Generic name | MOR106 single ascending doses, intravenous |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MOR106 single ascending doses, intravenous CI brief — competitive landscape report
- MOR106 single ascending doses, intravenous updates RSS · CI watch RSS
- Galapagos NV portfolio CI
Frequently asked questions about MOR106 single ascending doses, intravenous
What is MOR106 single ascending doses, intravenous?
MOR106 single ascending doses, intravenous is a Small molecule drug developed by Galapagos NV.
Who makes MOR106 single ascending doses, intravenous?
MOR106 single ascending doses, intravenous is developed by Galapagos NV (see full Galapagos NV pipeline at /company/galapagos-nv).
What development phase is MOR106 single ascending doses, intravenous in?
MOR106 single ascending doses, intravenous is in Phase 1.